68Ga-PSMA-11 PET represents the Tumoricidal effect of 223Ra in a patient with castrate-resistant metastatic prostate cancer

Clinical Nuclear Medicine

Volumn 41, Issue 9, 2016, Pages 695-696

  Ahmadzadehfar, Hojjat ^a   Schlenkhoff, Carl Diedrich ^a   Rogenhofer, Sebastian ^a   Yordanova, Anna ^a   Essler, Markus ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

223Ra; bone metastases; Ga PSMA; prostate cancer; radionuclide therapy

Indexed keywords

ABIRATERONE ACETATE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN GA 68; RADIUM CHLORIDE RA 223; TRACER; UNCLASSIFIED DRUG; (68GA)GLU-UREA-LYS(AHX)-HBED-CC; ANTINEOPLASTIC AGENT; ORGANOMETALLIC COMPOUND; RADIOISOTOPE; RADIUM;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CASTRATION RESISTANT PROSTATE CANCER; HUMAN; MALE; METASTASIS; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; BONE NEOPLASMS; PATHOLOGY; PROCEDURES; PROSTATE TUMOR; SECONDARY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; HUMANS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIUM; TREATMENT OUTCOME;

EID: 84978173119     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000001286     Document Type: Article

References (8)

1. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213-223.
2. Sartor O, Coleman R, Nilsson S, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15:738-746.
3. Ahmadzadehfar H, Rahbar K, Kurpig S, et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrateresistant metastatic prostate cancer: A two-centre study. EJNMMI Res. 2015; 5:114.
4. Zechmann CM, Afshar-Oromieh A, Armor T, et al. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41:1280-1292.
5. Ahmadzadehfar H, Eppard E, Kurpig S, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7:12477-12488.
6. Verburg FA, Pfister D, Heidenreich A, et al. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CTin relation to PSA levels, PSA doubling time andGleason score. Eur J Nucl Med Mol Imaging. 2016;43:397-403.
7. Mottaghy FM, Behrendt FF, Verburg FA. (68)Ga-PSMA-HBED-CC PET/CT: where molecular imaging has an edge over morphological imaging. Eur J Nucl Med Mol Imaging. 2016;43:394-396.
8. Sterzing F, Kratochwil C, Fiedler H, et al. (68)Ga-PSMA-11 PET/CT: A new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2016;43:34-41.